CNS Pharmaceuticals to Present at the Q2 Virtual Investor Summit

Rhea-AI Summary

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the Q2 Virtual Investor Summit on May 18, 2021, at 12:30 PM ET. CEO John Climaco will present key advancements in the company's development of cancer treatments. CNS is focused on Berubicin, targeting glioblastoma multiforme (GBM), with a promising 44% disease control rate in previous trials. The company also aims to start a Phase 2 trial for Berubicin this year. Management will engage in virtual one-on-one meetings with registered investors.

HOUSTON, May 11, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present at the Q2 Virtual Investor Summit on Tuesday, May 18^th at 12:30 PM ET.  

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A live video webcast will be accessible on the Events page in the Investors section of the Company's website (www.cnspharma.com) and will be archived for 90 days following the event.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. During 2021, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial (with extensive PK) in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.

For more information, please visit www.CNSPharma.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-q2-virtual-investor-summit-301288082.html

SOURCE CNS Pharmaceuticals, Inc.

FAQ

When is CNS Pharmaceuticals presenting at the Q2 Virtual Investor Summit?

CNS Pharmaceuticals will present at the Q2 Virtual Investor Summit on May 18, 2021, at 12:30 PM ET.

What is the focus of CNS Pharmaceuticals' presentation at the summit?

The presentation will focus on CNS Pharmaceuticals' advancements in novel treatments for primary and metastatic cancers, particularly Berubicin for glioblastoma multiforme.

What is the disease control rate reported for Berubicin in trials?

Berubicin showed a 44% disease control rate in a completed Phase 1 clinical trial.

What clinical trials does CNS Pharmaceuticals plan for Berubicin in 2021?

CNS Pharmaceuticals expects to commence a Phase 2 clinical trial for Berubicin for glioblastoma multiforme in the U.S. in 2021.

How can investors participate in the Q2 Virtual Investor Summit?

Qualified members of the investor community can register for the conference and participate in virtual one-on-one meetings.